WallStreetZenWallStreetZen

NASDAQ: ONCY
Oncolytics Biotech Inc Stock

$1.40+0.30 (+27.27%)
Updated Oct 7, 2024
ONCY Price
$1.40
Fair Value Price
$0.34
Market Cap
$107.60M
52 Week Low
$0.84
52 Week High
$2.07
P/E
-5.13x
P/B
8.17x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.46M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.75
Operating Cash Flow
-$19M
Beta
1.14
Next Earnings
Nov 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ONCY Overview

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ONCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ONCY ($1.40) is overvalued by 313.4% relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ONCY ($1.40) is not significantly undervalued (313.4%) relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ONCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ONCY due diligence checks available for Premium users.

Be the first to know about important ONCY news, forecast changes, insider trades & much more!

ONCY News

Valuation

ONCY fair value

Fair Value of ONCY stock based on Discounted Cash Flow (DCF)
Price
$1.40
Fair Value
$0.34
Overvalued by
313.40%
ONCY ($1.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ONCY ($1.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ONCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ONCY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.13x
Industry
-111.33x
Market
26.63x

ONCY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.17x
Industry
5.95x
ONCY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ONCY's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.3M
Profit Margin
0%
ONCY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$23.4M
Liabilities
$10.0M
Debt to equity
0.75
ONCY's short-term assets ($22.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONCY's short-term assets ($22.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONCY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ONCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.0M
Investing
-$113.1k
Financing
$1.4M
ONCY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ONCY vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ONCY$107.60M+27.27%-5.13x8.17x
ANVS$107.04M-2.50%-1.82x-61.14x
KPTI$108.47M-1.92%-1.05x-0.82x
COYA$108.68M-1.65%-9.78x3.08x
PRLD$108.95M-1.00%-1.10x0.60x

Oncolytics Biotech Stock FAQ

What is Oncolytics Biotech's quote symbol?

(NASDAQ: ONCY) Oncolytics Biotech trades on the NASDAQ under the ticker symbol ONCY. Oncolytics Biotech stock quotes can also be displayed as NASDAQ: ONCY.

If you're new to stock investing, here's how to buy Oncolytics Biotech stock.

What is the 52 week high and low for Oncolytics Biotech (NASDAQ: ONCY)?

(NASDAQ: ONCY) Oncolytics Biotech's 52-week high was $2.07, and its 52-week low was $0.84. It is currently -32.37% from its 52-week high and 66.67% from its 52-week low.

How much is Oncolytics Biotech stock worth today?

(NASDAQ: ONCY) Oncolytics Biotech currently has 76,857,199 outstanding shares. With Oncolytics Biotech stock trading at $1.40 per share, the total value of Oncolytics Biotech stock (market capitalization) is $107.60M.

Oncolytics Biotech stock was originally listed at a price of $6.26 in Jun 1, 2018. If you had invested in Oncolytics Biotech stock at $6.26, your return over the last 6 years would have been -77.64%, for an annualized return of -22.09% (not including any dividends or dividend reinvestments).

How much is Oncolytics Biotech's stock price per share?

(NASDAQ: ONCY) Oncolytics Biotech stock price per share is $1.40 today (as of Oct 7, 2024).

What is Oncolytics Biotech's Market Cap?

(NASDAQ: ONCY) Oncolytics Biotech's market cap is $107.60M, as of Oct 8, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Oncolytics Biotech's market cap is calculated by multiplying ONCY's current stock price of $1.40 by ONCY's total outstanding shares of 76,857,199.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.